This targeted approach releases microbial neoantigens from killed bacteria and restores tumor metabolite balance (e.g., reducing immunosuppressive Kyn), activating CD8+ T cell responses that synergize with ICIs (289). The gene discussed is CD8A; the disease is neoplasm.